Science Magazine Podcast A new generation of radiotherapies for cancer, and why we sigh
Oct 2, 2025
Robert F. Service, a staff writer specializing in nuclear medicine, discusses the latest advancements in radiopharmaceuticals, highlighting their ability to target cancer cells with unprecedented precision. Maria Clara Novaes-Silva, a doctoral student from ETH Zurich, explores the intriguing mechanics of sighing and its role in lung health, noting how deep breaths can optimize lung function and potentially improve outcomes for ventilated patients. Together, they bring fresh insights into the realms of cancer treatment and respiratory physiology.
AI Snips
Chapters
Transcript
Episode notes
Targeted Radioactive Drugs Kill Cancer Cells
- Radiopharmaceuticals pair radioactive atoms with targeting molecules to deliver radiation directly to cancer cells.
- The approach builds on decades of molecular biology identifying cell-surface receptors unique to tumors.
Isotope Half-Lives Create A Timed Supply Chain
- Medical isotopes must be short-lived so patients get therapy but avoid prolonged radiation exposure.
- Short half-lives force tight, timed supply chains from production to patient use.
Alpha Versus Beta Radiation Tradeoffs
- Different isotopes differ by half-life and particle type (alpha vs beta), altering range and DNA damage.
- Alpha emitters deliver higher, localized damage; betas travel farther and suit diffused tumors.